Key result
Large-dose remifentanil reduced mean cerebral blood flow velocity by 31% compared to no change with moderate-dose remifentanil in patients undergoing CABG surgery.
Why the study?
Does large-dose remifentanil reduce cerebral blood flow velocity compared to moderate-dose remifentanil in patients undergoing elective coronary artery bypass graft surgery?
Does large-dose remifentanil reduce cerebral blood flow velocity compared to moderate-dose remifentanil in patients undergoing elective coronary artery bypass graft surgery?
Large-dose, but not moderate-dose, remifentanil reduces cerebral blood flow velocity independent of systemic hemodynamics in isocapnic cardiac patients.
Answers are grounded in this paper and cite their sources.
May warrant caution with large-dose remifentanil in CABG; leaves open effects on neurologic outcomes pending randomized data.
In the present study, we investigated the effect of remifentanil on cerebral blood flow velocity (CBFV).We investigated 20 patients (ASA physical status III) scheduled for elective coronary artery bypass graft surgery. Anesthesia was induced with remifentanil 5 [micro sign]g/kg IV (Group 1, n = 10) or 2 [micro sign]g/kg IV (Group 2, n = 10) and was maintained with 3 [micro sign]g [center dot] kg-1 [center dot] min-1 IV (Group 1) or 1 [micro sign]g [center dot] kg-1 [center dot] min-1 IV (Group 2). Pancuronium (0.1 mg/kg IV) was administered for muscle relaxation. Assisted ventilation followed by controlled ventilation via a mask was performed with the PaCO2 kept constant. Mean cerebral blood flow velocity (Vmean) was measured in the middle cerebral artery using a transcranial Doppler sonography system. Mean arterial pressure (MAP) was kept constant by the IV administration of norepinephrine. Measurements were made at baseline and every minute after remifentanil infusion for 10 min. Data were analyzed by using analysis of variance and a post hoc t-test (P < 0.05). Heart rate, MAP, and PaCO2 did not change over time in either group. Vmean did not change in Group 2. In contrast, there was a 31% decrease of Vmean in Group 1 (P < 0.05). The results show that large-dose, but not moderate-dose, remifentanil reduces CBFV unrelated to any changes in systemic hemodynamics in isocapnic cardiac patients. Implications: Transcranial Doppler sonography was used to monitor remifentanil-induced changes in cerebral perfusion. We found that large doses of remifentanil reduced cerebral blood flow velocity despite constant perfusion pressure. This may implicate a central mechanism for cerebral hemodynamic effects of remifentanil. (Anesth Analg 1998;87:569-73)
No takes yet. Share an insight, caveat, or question.
Paris et al. (1998) studied Coronary artery disease requiring bypass graft surgery (n=20). Remifentanil vs. Moderate-dose remifentanil (2 µg/kg IV induction, 1 µg/kg/min maintenance) was evaluated on Mean cerebral blood flow velocity (Vmean) (31% decrease, p=<0.05). Large-dose remifentanil reduced mean cerebral blood flow velocity by 31% compared to no change with moderate-dose remifentanil in patients undergoing CABG surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: